ES542948A0 - Un procedimiento para preparar disposiciones de hidrogel portadoras de agente activo - Google Patents

Un procedimiento para preparar disposiciones de hidrogel portadoras de agente activo

Info

Publication number
ES542948A0
ES542948A0 ES542948A ES542948A ES542948A0 ES 542948 A0 ES542948 A0 ES 542948A0 ES 542948 A ES542948 A ES 542948A ES 542948 A ES542948 A ES 542948A ES 542948 A0 ES542948 A0 ES 542948A0
Authority
ES
Spain
Prior art keywords
active agent
hydrogel
carriing
provisions
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES542948A
Other languages
English (en)
Spanish (es)
Other versions
ES8603273A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of ES8603273A1 publication Critical patent/ES8603273A1/es
Publication of ES542948A0 publication Critical patent/ES542948A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Colloid Chemistry (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Plant Substances (AREA)
ES542948A 1984-05-10 1985-05-09 Un procedimiento para preparar disposiciones de hidrogel portadoras de agente activo Granted ES542948A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/608,756 US4624848A (en) 1984-05-10 1984-05-10 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use

Publications (2)

Publication Number Publication Date
ES8603273A1 ES8603273A1 (es) 1986-01-01
ES542948A0 true ES542948A0 (es) 1986-01-01

Family

ID=24437841

Family Applications (1)

Application Number Title Priority Date Filing Date
ES542948A Granted ES542948A0 (es) 1984-05-10 1985-05-09 Un procedimiento para preparar disposiciones de hidrogel portadoras de agente activo

Country Status (16)

Country Link
US (1) US4624848A (Sortimente)
EP (1) EP0164311B1 (Sortimente)
JP (1) JPS619A (Sortimente)
AT (1) ATE61731T1 (Sortimente)
AU (1) AU583507B2 (Sortimente)
CA (1) CA1246447A (Sortimente)
DE (1) DE3582193D1 (Sortimente)
DK (1) DK205185A (Sortimente)
ES (1) ES542948A0 (Sortimente)
FI (1) FI851801L (Sortimente)
GR (1) GR851114B (Sortimente)
IL (1) IL75129A (Sortimente)
NZ (1) NZ212030A (Sortimente)
PH (1) PH24100A (Sortimente)
PT (1) PT80416B (Sortimente)
ZA (1) ZA853511B (Sortimente)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
JPH0643851B2 (ja) * 1986-03-13 1994-06-08 大同メタル工業株式会社 軸受ユニット
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4780236A (en) * 1986-06-20 1988-10-25 Kiwi Brands, Inc. Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
GB8620845D0 (en) * 1986-08-28 1986-10-08 Reckitt & Colmann Prod Ltd Treatment of textile surfaces
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
EP0297650A1 (en) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions with controlled zero-order delivery rate and method of preparing these compositions
US4910015A (en) * 1987-10-19 1990-03-20 Massachusetts Institute Of Technology Surface-active polysiloxanes and drug releasing materials thereof
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
WO1996024330A1 (en) 1995-02-10 1996-08-15 Medtronic, Inc. Method and device for administering analgesics
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
BR0016708A (pt) 1999-12-23 2002-10-08 Pfizer Prod Inc Forma de dosagem de droga baseada em hidrogel
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
ES2271301T3 (es) * 2001-07-23 2007-04-16 Alcon, Inc. Dispositivo de suministro de farmaco oftalmico.
CN1203814C (zh) 2001-07-23 2005-06-01 爱尔康公司 眼部药物输送装置
EP1441703B1 (en) * 2001-10-29 2018-01-03 Massachusetts Institute of Technology Zero-order release profile dosage form manufactured by three-dimensional printing
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0310636D0 (en) * 2003-05-08 2003-06-11 Nektar Therapeutics Uk Ltd Particulate materials
BRPI0409962A (pt) 2003-05-08 2006-04-25 Nektar Therapeutics Uk Ltd co-formulação particulada de uma substáncia ativa e um excipiente, composição farmacêutica ou nutricêutrica, produto farmacêutico ou nutricêutico, método para preparar uma co-formulação particulada de uma substáncia ativa e um excipiente, e, uso de uma substáncia ativa e um excipiente
EP1684669A4 (en) * 2003-07-10 2008-01-02 Alcon Inc DEVICE FOR RELEASING AN OPHTHALMIC MEDICINAL PRODUCT
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CA2623940C (en) 2005-09-27 2017-01-10 Tissuetech, Inc. Amniotic membrane preparations and purified compositions and methods of use
NZ568700A (en) 2005-11-28 2012-03-30 Marinus Pharmaceuticals Solid stabilized particulate formulations comprising ganaxolone
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
WO2008079440A2 (en) 2006-07-10 2008-07-03 Medipacs, Inc. Super elastic epoxy hydrogel
WO2008021368A2 (en) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions and methods for neuroprotection
NZ601278A (en) 2006-09-22 2013-09-27 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
BRPI0816326A2 (pt) 2007-09-10 2015-03-24 Calcimedica Inc Compostos que modulam cálcio intracelular
JP2011505520A (ja) 2007-12-03 2011-02-24 メディパックス インコーポレイテッド 流体計量供給装置
MY157445A (en) 2008-08-27 2016-06-15 Calcimedica Inc Compounds that modulate intracellular calcium.
EP2421901B1 (en) 2009-04-24 2015-10-28 Tissue Tech, Inc. Compositions containing hc ha complex and methods of use thereof
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
HUE029570T2 (en) 2010-04-27 2017-03-28 Calcimedica Inc Intracellular calcium modifying compounds
EP2563759B1 (en) 2010-04-27 2022-04-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2575818A4 (en) 2010-06-03 2013-11-06 Pharmacyclics Inc USE OF BRUTON TYROSINE KINASE INHIBITORS (BTK)
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
WO2012149486A1 (en) 2011-04-28 2012-11-01 Tissuetech, Inc. Methods of modulating bone remodeling
WO2012170905A1 (en) 2011-06-10 2012-12-13 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
WO2013039488A1 (en) 2011-09-13 2013-03-21 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
ES2982694T3 (es) 2012-01-06 2024-10-17 H Lundbeck As Compuestos de carbamato para su uso en tratamiento
EP2847249A4 (en) 2012-03-14 2016-12-28 Medipacs Inc Smart polymer materials with excess reactive molecules
CA2875986C (en) 2012-06-04 2020-06-09 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
ES2846789T3 (es) 2012-07-11 2021-07-29 Tissuetech Inc Composiciones que contienen complejos HC-HA/PTX3 y métodos de uso de los mismos
US9416141B2 (en) 2012-09-28 2016-08-16 University Of Washington Through Its Center For Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
KR20160093675A (ko) 2013-12-05 2016-08-08 파마싸이클릭스 엘엘씨 브루톤 티로신 키나제의 억제제
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
JP6697808B2 (ja) 2015-02-06 2020-05-27 ユニヴァーシティ オブ ワシントン 感覚有毛細胞の死を防ぐまたは処置するための化合物と方法
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
EP3261631B1 (en) 2015-02-27 2025-09-10 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
BR112017024253A2 (pt) 2015-05-11 2018-07-24 Abide Therapeutics Inc métodos de tratamento de inflamação ou dor neuropática.
US10342831B2 (en) 2015-05-20 2019-07-09 Tissuetech, Inc. Composition and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
JP2018525411A (ja) 2015-08-31 2018-09-06 ファーマサイクリックス エルエルシー 多発性骨髄腫を治療するためのｂｔｋ阻害剤の組み合わせ
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
FI3827838T3 (fi) 2015-12-16 2023-06-19 Walter & Eliza Hall Inst Medical Res Sytokiini-indusoidun sh2-proteiinin estäminen nk-soluissa
ES3041841T3 (en) 2016-01-19 2025-11-14 Janssen Pharmaceutica Nv Formulations/compositions comprising a btk inhibitor
MX2018008771A (es) 2016-01-19 2018-11-09 Janssen Pharmaceutica Nv Formulaciones/composiciones que comprenden un inhibidor de btk.
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
ES3039958T3 (en) 2016-04-04 2025-10-27 Sinopia Biosciences Inc Treating levodopa-induced dyskinesia using trapidil
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. MEDICINAL PRODUCTS BASED ON PHENOLIC TRPV1 AGONISTS IN ASSOCIATION WITH LOCAL ANESTHETICS AND VASOCONSTRUCTS TO IMPROVE LOCAL ANESTHESIA
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US11090702B2 (en) * 2016-06-28 2021-08-17 Trustees Of Tufts College Compositions and methods for delivery of active agents
ES2964344T3 (es) 2016-07-18 2024-04-05 Arthrosi Therapeutics Inc Proceso para fabricar hidroxi-benzbromarona deuterada y productos intermedios de la misma
SG11201901679XA (en) 2016-08-26 2019-03-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
HUE056973T2 (hu) 2016-11-16 2022-04-28 H Lundbeck As MAGL inhibitor kristályos formája
CA3043609A1 (en) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Pharmaceutical formulations
CN111315385A (zh) 2017-09-01 2020-06-19 华盛顿大学 用于预防或治疗感觉毛细胞死亡的化合物的晶型
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
WO2020023794A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
US12419854B2 (en) 2018-12-06 2025-09-23 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
CN113226302B (zh) 2018-12-06 2023-08-18 广州瑞安博医药科技有限公司 用于治疗或预防痛风或高尿酸血症的化合物的晶型
EP3906026A4 (en) 2018-12-31 2022-10-19 Biomea Fusion, LLC Irreversible inhibitors of menin-mll interaction
EP3937938A1 (en) 2019-03-15 2022-01-19 Unicycive Therapeutics Inc. Nicorandil derivatives
MX2022013224A (es) 2020-04-21 2022-11-14 H Lundbeck As Sintesis de un inhibidor de la monoacilglicerol lipasa.
US12435085B2 (en) 2020-05-11 2025-10-07 Casi Pharmaceuticals, Inc. Crystalline forms and formulations of a VCP/p97 inhibitor
CA3202151A1 (en) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
WO2022150525A1 (en) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma in the treatment of alcohol use disorder
WO2022238507A1 (en) 2021-05-11 2022-11-17 Awakn Ls Europe Holdings Limited Therapeutic aminoindane compounds and compositions
WO2022256720A2 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use
EP4384179A1 (en) 2021-08-11 2024-06-19 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
TW202313004A (zh) 2021-08-20 2023-04-01 美商拜歐米富士恩股份有限公司 Ｍｅｎｉｎ－ｍｌｌ相互作用之不可逆抑制劑的結晶形式
US12180176B2 (en) 2021-08-23 2024-12-31 Alexander Shulgin Research Institute, Inc. Fluorinated empathogens
WO2023028091A1 (en) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Deuterated empathogens
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
KR20240054333A (ko) 2021-08-31 2024-04-25 세레스파이어 인코포레이티드 공결정
WO2023034645A2 (en) 2021-09-03 2023-03-09 Alexander Shulgin Research Institute Asymmetric allyl tryptamines
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
WO2023049480A1 (en) 2021-09-25 2023-03-30 Alexander Shulgin Research Institute Substituted phenylalkylamines
US20250066386A1 (en) 2021-11-09 2025-02-27 Biomea Fusion, Inc. Inhibitors of kras
WO2023129667A1 (en) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Pyrazine compounds as inhibitors of flt3
CA3249142A1 (en) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited 1,3-BENZODIOXOLE ESTERS AND THEIR THERAPEUTIC USE
WO2023156565A1 (en) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Bridged ring compounds and their therapeutic use as cns agents
US20250353854A1 (en) 2022-06-03 2025-11-20 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
JP2025524598A (ja) 2022-07-06 2025-07-30 オピラン ファーマ リミテッド Ｓ１ｐ受容体モジュレーターの結晶形態
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
US20250145571A1 (en) 2023-09-26 2025-05-08 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil
WO2025194102A1 (en) 2024-03-15 2025-09-18 Unicycive Therapeutics, Inc. Pyridine modified nicorandil derivatives

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
FR1586811A (Sortimente) * 1966-01-06 1970-03-06
US3660563A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a drug
US3660071A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a pesticide
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1394990A (en) * 1971-08-12 1975-05-21 Hydrophilics Int Inc Copolymers and compositions containing copolymers
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US4007258A (en) * 1973-09-10 1977-02-08 Union Corporation Sustained release pesticidal composition
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
CH621561A5 (en) * 1974-01-14 1981-02-13 Ceskoslovenska Akademie Ved Process for producing a bromocyan-activated, hydrophilic, polymeric carrier for biologically active compounds in dried form
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
DE2908794C2 (de) * 1978-03-09 1984-09-13 Japan Atomic Energy Research Institute, Tokio/Tokyo Verfahren zur Herstellung eines eine physiologisch aktive Substanz enthaltenden Polymerpräparates
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device

Also Published As

Publication number Publication date
NZ212030A (en) 1988-01-08
US4624848A (en) 1986-11-25
FI851801A7 (fi) 1985-11-11
ES8603273A1 (es) 1986-01-01
DE3582193D1 (de) 1991-04-25
JPS619A (ja) 1986-01-06
FI851801L (fi) 1985-11-11
CA1246447A (en) 1988-12-13
GR851114B (Sortimente) 1985-11-25
ZA853511B (en) 1985-12-24
EP0164311A2 (en) 1985-12-11
FI851801A0 (fi) 1985-05-08
IL75129A0 (en) 1985-09-29
AU583507B2 (en) 1989-05-04
EP0164311A3 (en) 1987-06-03
PT80416A (en) 1985-06-01
PT80416B (en) 1987-04-16
EP0164311B1 (en) 1991-03-20
AU4221685A (en) 1985-11-14
ATE61731T1 (de) 1991-04-15
IL75129A (en) 1989-08-15
PH24100A (en) 1990-03-05
DK205185A (da) 1985-11-11
DK205185D0 (da) 1985-05-09

Similar Documents

Publication Publication Date Title
ES542948A0 (es) Un procedimiento para preparar disposiciones de hidrogel portadoras de agente activo
ES545679A0 (es) Procedimiento para producir un comprimido de dispensacion de un principio biologicamente activo.
AR225478A1 (es) Metodo para preparar una formulacion farmaceutica seca de liberacion y accion prolongada,controlada,que contiene un agente terapeutico y un portador seco,metodo para preparar dicho portador seco y portador seco asi preparado
ES2001897A6 (es) Procedimiento para la fabricacion de una tableta de liberacion controlada
EP0013606A3 (en) Polymeric diffusion matrix, method of its preparation and drug delivery device comprising said matrix
BR8103649A (pt) Dispositivo e processo para a liberacao controlade de um material ativo em um meio liquido processo para fazer um corpo soluvel ser humano ou animal
ES2194232T3 (es) Reservorio de espuma polimerica para dispositivo de aporte por electrotransporte.
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
ATE12731T1 (de) Polymere diffusionsmatrix und verfahren zu deren herstellung.
Lee et al. Fluoride ion diffusion from a glass–ionomer cement
AR220113A1 (es) Composiciones fungicidas que contienen n-benzoilantranilatos como agente activo,procedimiento para prepararlas y nuevos n-benzoilantranilatos de aplicacion en dichas composiciones
FR1253269A (fr) Procédé et dispositif d'immobilisation automatique notamment pour aérodynes et, plus particulièrement, pour hélicoptères
Escolar et al. Effect of low temperatures on glucose-induced insulin secretion and ionic fluxes in rat pancreatic islets
NO20005725D0 (no) Biologisk aktiv sammensetning
MX5150E (es) Procedimiento para preparar un copolimero de bloque hidrofilico que contiene un agente biologicamente activo
JPS55149212A (en) Gradually releasing preparation of methotrexate
JPS52130980A (en) Immobilization of glucoseisomerase
JPS52120136A (en) Hair treating composition

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19960603